Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 75 years of age or older.
- People who were admitted to hospital due to chest pain (angina) or other symptoms related to coronary heart disease.
- People who have been diagnosed with coronary heart disease, confirmed by at least one of the following: a coronary angiogram or CT scan of the heart arteries done during this hospital stay; a previous coronary angiogram or CT scan showing coronary heart disease; or a diagnosis made by the treating doctor based on symptoms, medical history, heart tests, or other relevant investigations.
- People who are able to understand what the study involves, are willing to take part, and are able to sign a consent form.
Who may not be able to join:
- People who have a serious non-heart-related illness where life expectancy is not expected to exceed 6 months, such as advanced cancer or another end-stage condition.
- People who are unlikely to be able to participate in long-term follow-up appointments, such as those with severe memory or thinking problems, or a severe mental illness.
- People who passed away from a non-heart-related cause within 24 hours of being admitted to hospital.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
major adverse cardiovascular events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.